Core Insights - Actuate Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β) [1][4] - The company's lead investigational drug, elraglusib, targets molecular pathways involved in tumor growth and resistance to conventional cancer treatments, aiming to enhance anti-tumor immunity [4] Upcoming Investor Conferences - Actuate's President & CEO, Daniel Schmitt, will participate in the BIO CEO & Investor Conference on February 10, 2025, in New York, NY, which includes one-on-one meetings [2] - The company will also be present at the B. Riley Precision Oncology & Radiopharma Conference on February 28, 2025, in New York, NY, featuring a fireside chat and one-on-one meetings [3] Company Overview - Actuate Therapeutics is dedicated to developing therapies for challenging cancers, with elraglusib being a novel GSK-3β inhibitor that mediates anti-tumor immunity by inhibiting NF-kB and regulating immune checkpoints [4]
Actuate Therapeutics to Participate in Upcoming Investor Conferences in February